Explain this page
Arphra AIPlain-English read on Enliven Therapeutics, Inc.’s valuation06-11today
- Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares7d
- Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares7d
- Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants11d
- Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants11d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$3.40
-92.61% vs spot
Recommendation
Sell
3 of 3 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $65.25 (+41.97%)
Candlestick · 1Y
Open in chart workstation →ELVN
45.10+60.10%H 47.36L 25.29MA50 37.36MA200 —Avg vol 1.3M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.91% | +2.11% | +10.64% | +49.17% | +178.04% | +198.44% | +126.52% | +118.03% | +47.69% | -23.40% | -23.40% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$45.89
68 sh
Bid
$43.00
3 sh
Ask
$50.92
5 sh
Spread
$7.920
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $0 | -$29.67M | $-0.45 |
| Q3 Sep 2025 | $0 | -$20.15M | $-0.32 |
| Q2 Jun 2025 | $0 | -$25.34M | $-0.49 |
| Q1 Mar 2025 | $0 | -$28.54M | $-0.57 |
| Q4 Dec 2024 | $0 | -$23.18M | $-0.46 |
| Q3 Sep 2024 | $0 | -$23.16M | $-0.48 |
Sector & industry today
LiveSectors
- Real Estate+1.26%
- Industrials+1.00%
- Basic Materials+0.65%
- Energy+0.59%
- Healthcare+0.01%
- Utilities-0.07%
- Financial Services-0.24%
- Communication Services-0.55%
- Technology-0.80%
- Consumer Cyclical-0.85%
- Consumer Defensive-1.00%
Top industries (issuer's industry highlighted)
- Biotechnology+6.56%
- Financial - Mortgages-4.05%
- Electrical Equipment & Parts+3.88%
- Staffing & Employment Services-3.62%
- Software - Services-3.30%
- Software - Infrastructure-3.07%
- Advertising Agencies+2.92%
- Apparel - Footwear & Accessories-2.80%
- Engineering & Construction+2.80%
- Financial - Conglomerates+2.62%
- Luxury Goods+2.47%
- Hardware, Equipment & Parts+2.34%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Sharesprnewswire.com·Jun 15, 2026
- Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Sharesprnewswire.com·Jun 15, 2026
- Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrantsgurufocus.com·Jun 11, 2026
- Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrantsprnewswire.com·Jun 11, 2026
- Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrantsprnewswire.com·Jun 11, 2026
- Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsprnewswire.com·Jun 11, 2026
- Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsprnewswire.com·Jun 11, 2026
- Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcriptseekingalpha.com·Jun 11, 2026
Recent analyst activity
DB- Jun 08, 2026PT$60.00Enliven initiated with a Buy at StifelStifel Nicolaus
- Jun 02, 2026PT$62.00Enliven Therapeutics (ELVN) PT Raised to $62 at MizuhoMizuho Securities
Peers
No peer list available for ELVN.
Total assets
$476.17M
Total debt
$399K
Cash & equiv
$98.9M
Operating CF
-$70.3M
Free cash flow
-$70.46M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $0 | -$119.66M | -$103.69M | $-1.83 | — |
| FY 2024 | $0 | -$104.55M | -$89.02M | $-1.89 | — |
| FY 2023 | $0 | -$83.53M | -$71.58M | $-2.01 | — |
| FY 2022 | $0 | -$38.79M | -$37.66M | $-6.03 | — |
| FY 2021 | $0 | -$24.76M | -$24.74M | $-3.17 | — |